得力生注射液联合化疗治疗晚期消化道肿瘤的临床观察  

The clinical study on Treatment of DLS combined with chemotherapy for advanced gastrointestinal cancer

作　　者：尚育红[1] 蒿黎[1] 李格林[1] 范魁生[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450052

出　　处：《临床肿瘤学杂志》2006年第7期518-520,共3页Chinese Clinical Oncology

摘　　要：目的:探讨得力生注射液(DeLiShengInjection,简称DLS)联合化疗治疗晚期消化道肿瘤的临床疗效。方法:60例晚期消化道肿瘤患者随机分组为化疗组(对照组)和化疗联合得力生组(试验组),其中试验组30例,奥沙利铂135mg/m2+5%葡萄糖溶液(GS)250ml静滴,d1;亚叶酸钙(CF)100mg+5%GS250ml静滴,d1～d5;氟尿嘧啶(5FU)0.5g+5%GS500ml静滴,d1～d5。化疗当天给予得力生注射液20～40ml加入5%GS500ml静滴d1～d21。常规予5HT3受体抑制剂止吐,21～28天为1周期。对照组30例,化疗方案同治疗组。结果:对照组总有效率和生活质量改善率分别为39.4%和42.4%,试验组分别为63.9%和66.7%,两组比较有显著性差异(P<0.05);对照组白细胞减少为75.8%,高于试验组的52.8%;对照组治疗后CD3+、CD4+、CD4+/CD8+降低,CD8+增高,治疗前后对比有非常显著性差异(P<0.01),而试验组治疗前后无显著性差异。结论:得力生联合化疗可显著提高化疗疗效,增强机体免疫功能,改善患者的生存质量,且不增加骨髓抑制。Objective：To study the effects of De Li Sheng Injection with chemotherapy in the treatment of gastrointestinal cancer. Methods：60 cases of advanced gastrointestinal cancers were randomly divided into two groups, 30 patients in control group （chemotherapy） ,30 patients in test group（ De Li Sheng Injectable combined with chemotherapy ）. Results：Total remission rate and improvement rate of quality of life of control gnoup were 39.4% and 42.4% respectively ,while they were 63.9% and 66. 7% respectively in test group. Test group was obviously superior to control group in therapeutic effect （ P 〈 0. 05 ）. The leucocyte decrease rate of control group was 75.8% which was higher than 52.8% in test group（ P 〈 0. 05 ）. CD3 ^＋ ,CD4^ ＋ ,CD4^ ＋/CD8^ ＋ decreased, CD8^ ＋ ascended （P 〈 0. 01 ） in control group and it changed slightly in test group. Conclusion ： DLS conbined with chemotherapy may significantly enhance the chemotherapy effects ,increase immunity function of patients, improve the quality of life, whereas do not increase myelosuppresion.

关 键 词：得力生 消化道肿瘤 晚期 

分 类 号：R730.59[医药卫生—肿瘤]